Protech Home Medical (Vancouver: PTQ) (OTC: PTQFF) provides in-home monitoring and disease management services, notes Ryan Irvine, founder of KeyStone Financial, a contributing editor to Internet Wealth Builder and a participant in the MoneyShow Canada Premier Virtual Investor Conference on Feb. 2-4.
The firm's services include end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions.
The primary business objective of the company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management.
The company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.
The company remains focused on strategically layering on complimentary respiratory focused businesses to its strong infrastructure where the company can quickly deploy its technology driven model to enhance sales, margins, and patient count over time.
Management reported that the acquisition pipeline remains robust and the company expects 2021 to be a very busy year as Protech scales up the organization by further penetrating existing markets as well as entering new markets.
With over $28 million in cash and an untapped US$20 million revolving credit facility with CIT Bank’s Healthcare Division, management believes that the company is in the strongest position in its history to aggressively match organizational growth with the level of capital markets exposure.
The acquisition focus continues to be on profitable $5 to $20+ million-dollar top-line companies, and management stated Protech currently has a very deep pipeline of targets at various stages of due-diligence.
On January13, Protech announced that it has applied to list its common shares on the Nasdaq Capital Market. Despite the jump in the shares, we continue to believe it trades at a discount to its peers and maintain our "Buy" rating.
